Ignis Therapeutics
- Biotech or pharma, therapeutic R&D
Ignis is a CNS-focused biotech with specialized expertise and full-cycle capabilities from discovery to clinical to commercialization. Led by experienced executives like CEO Dr. Eileen Long (ex Sanofi CNS China CEO) and backed by SKBP, Mubadala, HBM, GS, etc.,
The company has a strong pipeline with three China near-term commercialization assets (Cenobamate, Solriamfetol, & Monarch eTNS), seveval US IND enabled/PCC stage assets with interest to look for global partners to accelerate the devleopment and maximize the asset value.
A de-risked business model with Cenobamate and Solriamfetol made NDA submissions to China FDA in Nov 2024. Its current cash reserves, bolstered by this crossover round and IPO, will drive operations to cash flow positivity, ensuring strategic flexibility for future growth.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}